Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pridopidine in Amyotrophic Lateral Sclerosis
NCT07322003Phase 3Recruiting
- Sponsor
- Prilenia Therapeutics
- Start
- Feb 2026
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 13
01
Overview
A Phase 3 trial of pridopidine in amyotrophic lateral sclerosis (ALS), sponsored by Prilenia Therapeutics. Started Feb 2026; status: recruiting.
02
Drugs
pridopidine
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT07322003.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07322003.